Advanced in Neuroendocrine Tumor

Geir O. Hjortland

Oslo, NO 
Advanced in Neuroendocrine Tumor
Oslo, NO 
OverviewLocationsClinical Research

Overview

Geir Hjortland practices in Oslo, Norway. Hjortland is rated as an Advanced expert by MediFind in the treatment of Neuroendocrine Tumor. Their top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 26 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 15 articles in the study of Neuroendocrine Tumor.

Locations

Oslo, Norway
Other Locations
Nydalen, 0424, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC-study) - a Phase I/II Trial
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC-study) - a Phase I/II Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 22, 2023
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Nivolumab, Chemotherapy
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

26 Total Publications

Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.
Journal: British journal of cancer
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hjortland's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile